Paean Biotechnology is developing
anti-inflammatory and anti-cancer drugs based on mitochondria separated from
human umbilical cord-mesenchymal stem cell (UC-MSC).
Paean Biotechnology is developing anti-inflammatory and anti-cancer drugs based on mitochondria separated from human umbilical cord-mesenchymal stem cell (UC-MSC).
Mitochondria therapeutics is a therapeutic
agent based on mitochondria separated from stem cells, and includes PN-101 for
an inflammatory rare disease called multiple myositis and PN-102 for sepsis.
PN-201 of cell therapeutics is the cell
therapeutics using the mitochondria with amplified the anticancer effect by
delivering the mitochondria isolated from stem cells into NK cells. Protein
therapeutics is a therapeutic agent that uses a technology that uses "modified
mitochondria" made by combining PN-301 made by making anti-cancer protein to
mitochondria and PN-302 made by marking single antibody chain.
PN-101 has been confirmed for efficacy in a
disease animal model and has been tested for toxicity in a GLP institution, and
is in the process of preparing an IND for phase 1 clinical trial. PN-102 has
been confirmed to have a significant reduction in mortality in animals with
sepsis, and the mechanism of regulating immunity due to the cytokine storm in
hyperinflammatory conditions and immune paralysis that are immunological
characteristics of sepsis.
PN-201 has been confirmed the cancer cell
killing ability of mitochondrial-enhanced NK cells and the survival rate
increase in animal models, and patents were registered for intracellular
mitochondrial delivery and NK cell therapeutics including foreign mitochondria.
The platform technologies of PN-301 and
PN-302 include a technique for producing 'modified mitochondria" by connecting
a protein that induces apoptosis of recombinant cancer and a single-chain
variable fragment (scFv) antibody to the mitochondrial surface. We have
confirmed that "modified mitochondria" targets cancer cells and suppresses
tumor growth. Protein delivery technology using mitochondria is an innovative
platform technology that can be compared to antibody-drug conjugates that can
deliver various types of proteins into cells by targeting cells through scFv.
The products and services of the major
companies of KHIDI Health Industry Startup Innovation Center in the MIK Hot
Spot (Made in Korea Online Exhibition) will also be displayed in BIO KOREA
2020. Asia's biggest bio convention BIO KOREA 2020 co-organized by KHIDI and
Chungbuk Province and sponsored by MOHW will be open online due to the COVID-29
pandemic on May 18-23. Virtual exhibition halls, conference, and business
forums will be operated, and the companies will be promoting their
competitiveness. Also, with video meetings, businesses between overseas
speakers, buyers, and domestic and foreign participating companies will be
made. To date, more than 160 companies have applied for the virtual exhibition
booth at BIO KOREA 2020. Companies wishing to participate can apply through the
web page or email by Apr. 30.
The global news network AVING News has
begun holding the MIK Hot Spot (Made in Korea Online Exhibition) to help small
and medium-sized companies enter the market and attract investment 365 days a
year. AVING News has been running online exhibitions since 2005 and had 975
online exhibitions so far. Its YouTube online exhibition has placed itself as
Korea's largest online exhibition hall that opens with 19,000 videos (booths)
with more than 800,000 visits per month which means more than 10 million visits
The MIK Hot Spot online exhibition is
scheduled to be held regularly according to the field, target market, and
participating institutions, and it will be presented as a new type of online
business by transforming the know-hows and values of the participating
companies according to the trend. Companies that want to participate can apply
and apply through the marketing support projects from supporting institutions
in the local governments. Refer to the institutions for more information.